Eli Lilly shares new obesity drug trial weight loss data
Eli Lilly & Co released updated clinical trial results for its obesity drugs at the ObesityWeek 2026 medical conference.
EloraTZP shows major weight reduction
Lilly stated that overweight or obese adults with type 2 diabetes receiving EloraTZP lost up to an average of 23.3% of their body weight at 28 weeks. In addition, the firm stated that as many as 60 percent of individuals receiving the medication reached non-obese BMI standards within 48 weeks. EloraTZP also lowered average A1C readings by as much as 2.9%, enabling up to 77% of study subjects to achieve normal blood glucose.
Zepbound results for teen patients
Teens with obesity saw their BMI drop by a mean of 21.4% after 72 weeks on Zepbound. More than half of these adolescent patients dropped below the BMI threshold for obesity after the 72-week treatment period. During the study, participants also saw significant gains in weight-related quality of life, such as physical well-being.
Previous drug retatrutide performance
Earlier data showed Eli Lilly's experimental next-generation drug retatrutide achieved a greater therapeutic response than Novo Nordisk's Ozempic on blood sugar control. This previous study found retatrutide produced more than double the reduction in body weight in adults with type 2 diabetes compared to other treatments.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.